Enfusion, Inc. (NYSE:ENFN) Short Interest Down 17.7% in August

Enfusion, Inc. (NYSE:ENFN) was the target of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 1,900,000 shares, a decline of 17.7% from the August 15th total of 2,310,000 shares. Approximately 3.9% of the company’s stock are short sold. Based on an average daily volume of 374,600 shares, the days-to-cover ratio is presently 5.1 days.

Enfusion Price Performance

NYSE ENFN opened at $8.73 on Wednesday. The business’s fifty day moving average is $8.52 and its 200-day moving average is $8.87. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of 291.00, a PEG ratio of 2.23 and a beta of 0.90. Enfusion has a one year low of $7.52 and a one year high of $10.45.

Enfusion (NYSE:ENFN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $49.46 million during the quarter, compared to the consensus estimate of $50.27 million. Enfusion had a return on equity of 6.17% and a net margin of 1.98%. Research analysts expect that Enfusion will post 0.07 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Bronwen Bastone sold 18,241 shares of the business’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $8.11, for a total value of $147,934.51. Following the transaction, the insider now owns 198,913 shares in the company, valued at approximately $1,613,184.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 36.44% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enfusion

Institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC purchased a new stake in Enfusion during the first quarter valued at about $44,000. RiverPark Advisors LLC purchased a new stake in shares of Enfusion during the 2nd quarter valued at approximately $68,000. Arizona State Retirement System bought a new position in Enfusion in the 2nd quarter worth approximately $86,000. Price T Rowe Associates Inc. MD purchased a new position in Enfusion in the 1st quarter valued at approximately $102,000. Finally, Quadrature Capital Ltd purchased a new position in Enfusion in the 1st quarter valued at approximately $109,000. Hedge funds and other institutional investors own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.